請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73197
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林文澧(Win-Li Lin) | |
dc.contributor.author | Huei-Tyng Huang | en |
dc.contributor.author | 黃暉庭 | zh_TW |
dc.date.accessioned | 2021-06-17T07:21:59Z | - |
dc.date.available | 2022-07-17 | |
dc.date.copyright | 2019-07-17 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-03 | |
dc.identifier.citation | 1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
2. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011). 3. Massagué, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298–306 (2016). 4. Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B. &Sloan, E. K. Perioperative events influence cancer recurrence risk after surgery. Nat. Rev. Clin. Oncol. 15, 205–218 (2018). 5. Contursi, A., Sacco, A., Grande, R., Dovizio, M. & Patrignani, P. Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting. Cell. Mol. Life Sci. 74, 3491–3507 (2017). 6. Steeg, P. S. Targeting metastasis. Nat. Rev. Cancer 16, 201–218 (2016). 7. Barker, H. E., Paget, J. T. E., Khan, A. A. &Harrington, K. J. The Tumour Microenvironment after Radiotherapy : Mechanisms of Resistance and Recurrence. Nat Rev Cancer 15, 409–425 (2015). 8. Gotwals, P. et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17, 286–301 (2017). 9. Baskar, R., Lee, K. A., Yeo, R. &Yeoh, K. W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 9, 193–199 (2012). 10. Santivasi, W. L. &Xia, F. Ionizing Radiation-Induced DNA Damage, Response, and Repair. Antioxid. Redox Signal. 21, 251–259 (2014). 11. Peng, Y. et al. Cysteine protease cathepsin B mediates radiation induced bystander effects. Nature 547, 458–462 (2017). 12. Reynders, K., Illidge, T., Siva, S., Chang, J. Y. & DeRuysscher, D. The abscopal effect of local radiotherapy: Using immunotherapy to make a rare event clinically relevant. Cancer Treat. Rev. 41, 503–510 (2015). 13. Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA. Cancer J. Clin. 67, 65–85 (2017). 14. Cadena, A. et al. Radiation and Anti-Cancer Vaccines: A Winning Combination. Vaccines 6, 1–8 (2018). 15. Montico, B., Nigro, A., Casolaro, V. &Dal Col, J. Immunogenic apoptosis as a novel tool for anticancer vaccine development. Int. J. Mol. Sci. 19, 1–16 (2018). 16. Golden, E. B. &Apetoh, L. Radiotherapy and Immunogenic Cell Death. Semin. Radiat. Oncol. 25, 11–17 (2015). 17. Goldszmid, R. S. et al. Dendritic Cells Charged with Apoptotic Tumor Cells Induce Long-Lived Protective CD4+ and CD8+ T Cell Immunity against B16 Melanoma. J. Immunol. 171, 5940–5947 (2003). 18. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8 + T cells : Blood 114, 589–595 (2009). 19. Mortara, L., Frangione, V., Castellani, P., DeLerma Barbaro, A. & Accolla, R. S. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int. Immunol. 21, 655–665 (2009). 20. Weichselbaum, R. R., Liang, H., Deng, L. &Fu, Y. X. Radiotherapy and immunotherapy: A beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017). 21. Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 18, 313–322 (2018). 22. Ridolfi, L. et al. Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2. J. Transl. Med. 12, 1–11 (2014). 23. Barker, C. A. & Postow, M. A. Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes. Int. J. Radiat. Oncol. Biol. Phys. 88, 986–997 (2014). 24. Nikitina, E. Y. & Gabrilovich, D. I. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer 94, 825–833 (2001). 25. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015). 26. Vanpouille-Box, C. et al. TGFβ is a master regulator of radiation therapy-induced antitumor immunity. Cancer Res. 75, 2232–2242 (2015). 27. Wang, Y. W. et al. Metformin: A review of its potential indications. Drug Des. Devel. Ther. 11, 2421–2429 (2017). 28. Morales, D. R. &Morris, A. D. Metformin in Cancer Treatment and Prevention. Annu. Rev. Med. 66, 17–29 (2015). 29. Gronich, N. & Rennert, G. Beyond aspirin - Cancer prevention with statins, metformin and bisphosphonates. Nat. Rev. Clin. Oncol. 10, 625–642 (2013). 30. Jaune, E. &Rocchi, S. Metformin: Focus on melanoma. Front. Endocrinol. (Lausanne). 9, 1–9 (2018). 31. DeSouza Netoa, F. P. et al. Metformin: Oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma. Melanoma Res. 27, 536–544 (2017). 32. Zannella, V. E. et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin. Cancer Res. 19, 6741–6750 (2013). 33. Pearce, E. L. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 460, 103–107 (2009). 34. Eikawa, S. et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc. Natl. Acad. Sci. U. S. A. 112, 1809–1814 (2015). 35. Qin, G. et al. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology 7, e1442167 (2018). 36. Li, L. et al. Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer. Cancer Res. 78, 1779–1791 (2018). 37. Wang, Z. et al. Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair. Cancer Lett. 369, 192–201 (2015). 38. Storozhuk, Y. et al. Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. Br. J. Cancer 108, 2021–2032 (2013). 39. Koritzinsky, M. Metformin: A novel biological modifier of tumor response to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 93, 454–464 (2015). 40. Gash, K. J., Chambers, A. C., Cotton, D. E., Williams, A. C. &Thomas, M. G. Potentiating the effects of radiotherapy in rectal cancer: The role of aspirin, statins and metformin as adjuncts to therapy. Br. J. Cancer 117, 210–219 (2017). 41. Samsuri, N. A. B., Leech, M. &Marignol, L. Metformin and improved treatment outcomes in radiation therapy – A review. Cancer Treat. Rev. 55, 150–162 (2017). 42. Danciu, C. et al. Behaviour of four different B16 murine melanoma cell sublines: C57BL/6J skin. Int. J. Exp. Pathol. 96, 73–80 (2015). 43. Konopacka, M., Rogoliński, J. & Ślosarek, K. Bystander effects induced by direct and scattered radiation generated during penetration of medium inside a water phantom. Reports Pract. Oncol. Radiother. 16, 256–261 (2011). 44. Mairs, R. J., Fullerton, N. E., Zalutsky, M. R. &Boyd, M. Targeted Radiotherapy: Microgray Doses and the Bystander Effect. Dose-Response An Int. J. 5, 204–213 (2014). 45. Marín, A. et al. Bystander effects and radiotherapy. Reports Pract. Oncol. Radiother. 20, 12–21 (2015). 46. Scheffer, S. R. et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer 103, 205–211 (2003). 47. Desai, S. et al. Molecular understanding of growth inhibitory effect from irradiated to bystander tumor cells in mouse fibrosarcoma tumor model. PLoS One 11, 1–21 (2016). 48. Formenti, S. C. &Demaria, S. Radiation therapy to convert the tumor into an in situ vaccine. Int. J. Radiat. Oncol. Biol. Phys. 84, 879–880 (2012). 49. Wennerberg, E. et al. Barriers to radiation-induced in situ tumor vaccination. Front. Immunol. 8, 1–11 (2017). 50. Pereira, F. V. et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget 9, 25805–25825 (2018). 51. Gao, Y., Zhao, Z., Meng, X., Chen, H. &Fu, G. Migration and invasion in b16-f10 mouse melanoma cells are regulated by nrf2 inhibition during treatment with ionizing radiation. Oncol. Lett. 16, 1959–1966 (2018). 52. Sokolov, M.V. &Neumann, R. D. Radiation-Induced Bystander Effects in Cultured Human Stem Cells. PLoS One 5, e14195 (2010). 53. Prise, K. M. &O’Sullivan, J. M. Radiation-induced bystander signalling in cancer therapy. Nat. Rev. Cancer 9, 351–360 (2009). 54. Lara, P. C. et al. Direct and bystander radiation effects: A biophysical model and clinical perspectives. Cancer Lett. 356, 5–16 (2015). 55. Azzam, E. I., Toledo, S. M.De &Little, J. B. Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha-particle irradiated to nonirradiated cells. Proc. Natl. Acad. Sci. U. S. A. 98, 473–478 (2001). 56. Bazyar, S., Inscoe, C., Zhou, O. &Lee, Y. Z. Minibeam radiotherapy with small animal irradiators ; In vitro and in vivo feasibility studies. Phys Med Biol. 62, 8924–8942 (2017). 57. Chang, M. et al. Increased apoptotic potential and dose-enhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci. 99, 1479–1484 (2008). 58. Golden, E. B., Pellicciotta, I., Demaria, S., Barcellos-Hoff, M. H. &Formenti, S. C. The convergence of radiation and immunogenic cell death signaling pathways. Front. Oncol. 2, 1–13 (2012). 59. Tesniere, A. et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3–12 (2008). 60. Elmore, S. Apoptosis: A Review of Programmed Cell Death. Toxicol. Pathol. 35, 495–516 (2007). 61. Scharping, N. E., Menk, A.V., Whetstone, R. D., Zeng, X. &Delgoffe, G. M. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol. Res. 5, 9–16 (2017). 62. Kurtulus, S., Tripathi, P. &Hildeman, D. A. Protecting and rescuing the effectors: Roles of differentiation and survival in the control of memory T cell development. Front. Immunol. 3, 1–13 (2013). 63. Rzeszowska-Wolny, J., Przybyszewski, W. M. &Widel, M. Ionizing radiation-induced bystander effects, potential targets for modulation of radiotherapy. Eur. J. Pharmacol. 625, 156–164 (2009). 64. Nelson, E. E. &Guyer, A. E. High dose bystander effects in spatially fractionated radiation therapy. 1, 233–245 (2012). 65. Xue, L. Y., Butler, N. J., Makrigiorgos, G. M., Adelstein, S. J. &Kassis, A. I. Bystander effect produced by radiolabeled tumor cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 99, 13765–70 (2002). 66. Price, N. M., Rywlin, A. M. &Ackerman, A. B. Histologic criteria for the diagnosis of superficial spreading malignant melanoma: Formulated on the basis of proven metastatic lesions. Cancer 38, 2434–2441 (1976). 67. Susan, E. Apoptosis: A Reveiw of Programmed Cell Death. Toxicol. Pathol. 35, 496–516 (2007). 68. Wong, R. S. Y. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 30, (2011). 69. Lauber, K. et al. Apoptosis induction and tumor cell repopulation : The yin and yang of radiotherapy. Radiat. Oncol. 6, (2011). 70. Najafi M et al. The Mechanisms of Radiation-Induced Bystander Effect. J Biomed Phys Eng 4, 163–172 (2014). 71. Li, L. T., Jiang, G., Chen, Q. &Zheng, J. N. Predic Ki67 is a promising molecular target in the diagnosis of cancer (Review). Mol. Med. Rep. 11, 1566–1572 (2015). 72. Gimotty, P. A. et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J. Clin. Oncol. 23, 8048–8056 (2005). 73. Brix, N., Tiefenthaller, A., Anders, H., Belka, C. &Lauber, K. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. Immunol. Rev. 280, 249–279 (2017). 74. Wennerberg, E. et al. Immune recognition of irradiated cancer cells. Immunol. Rev. 280, 220–230 (2017). 75. Levy, A. et al. Can immunostimulatory agents enhance the abscopal effect of radiotherapy? Eur. J. Cancer 62, 36–45 (2016). 76. Reagan-Shaw, S., Nihal, M. &Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659–661 (2007). 77. Nair, A. &Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm. 7, 27–31 (2016). 78. Meera Saxena, G. C. Rebuilding cancer metastasis in the mouse. Mol. Oncol. 7, 283–296 (2013). 79. Ilmonen, S., Hernberg, M., Pyrhönen, S., Tarkkanen, J. &Asko-Seljavaara, S. Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma. Melanoma Res. 15, 375–381 (2005). | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/73197 | - |
dc.description.abstract | 研究背景與目的:癌症治療當前的困境是在癌轉移以及原位治療後癌復發的情形上無法有強而有效之抑制策略,此二現象同時亦為臨床上造成病人因癌症死亡之兩大宗理由。放射治療除了以放射線之高能量破壞癌細胞殺死癌腫瘤外,其特殊的致死機制亦會造成癌細胞免疫原性死亡,這些免疫原性死亡之癌細胞碎片被免疫系統辨識後可以被當作原位癌症疫苗,進而誘發體內的抗癌免疫反應。只是放射治療引發之抗癌免疫反應往往不夠有效,所以科學家們正致力於找出有效提升放射治療預後效果的可能方法。二甲雙胍為臨床上使用超過半世紀之糖尿病用藥,近年來研究亦相繼證明其與放射治療之協同療效、抗癌機制以及免疫調節能力,因此本研究選擇此藥物,模擬探討其是否能提升原位放射治療後對抗癌腫瘤再生成之抑制效應以及放射治療引發之旁觀者效應。
實驗材料與方法:本研究分成細胞實驗以及動物實驗,癌細胞株皆使用B16F10小鼠黑色素瘤細胞,小鼠品系為C57BL/6。細胞實驗給予二甲雙胍藥物以及將經放射線照射之癌細胞其原先培養環境裡的培養液拿去置換未照射之癌細胞的培養液,透過細胞存活率的分析,分別觀察二甲雙胍的癌毒殺效力以及放射線引發之旁觀者效應。另外,透過克隆檢驗、H&E染色以及TUNEL細胞凋亡檢定,觀察不同時間點下B16F10細胞株在不同劑量照射下之存活情形,以及接受高劑量放射線照射後之形態變化和細胞凋亡之情況。動物實驗分成兩個部分,分別討論預先給予放射線照射之癌細胞作為刺激與二甲雙胍兩者對於B16F10黑色素瘤細胞株腫瘤生成之抑制情形以及B16F10黑色素瘤之放射線引發之旁觀者效應。第一部分各組於第0天時於右側皮下接種1x105顆活的癌細胞,有預先照射放射線之癌細胞刺激的組別還會於第-14、-12、-10天分別於左背側皮下注入3x105顆甫接受75 Gy照射的癌細胞,模擬原位腫瘤接受放射治療時的原位癌症疫苗生成;第二部分除了在第0天種植活細胞時同時混合植入1x105顆甫照射完75 Gy放射線之癌細胞外,其餘條件皆與第一部分相同。兩部分動物實驗都分成四組,包括控制組、二甲雙胍組、預先注射經放射線照射之癌細胞刺激組以及預先注射經放射線照射之癌細胞刺激搭配二甲雙胍組,其中有服用二甲雙胍的組別每日給予的藥物劑量為200 mg/kg。此外,動物樣本部分,於第16天時犧牲小鼠取下腫瘤,做切片上的TUNEL檢定和H&E、Ki67、CD3+染色,並且對細胞凋亡相關標誌進行西方墨點法分析。 實驗結果:細胞存活率分析上,二甲雙胍在B16F10黑色素瘤上確實能有抑制腫瘤生長之毒殺效力;然而,培養液置換試驗中,於本研究的參數條件下並無法觀察到此細胞株的放射線引發之旁觀者效應。藉由克隆檢驗、H&E染色觀察以及TUNEL檢定分析,足以推論在照射75 Gy放射線後,B16F10黑色素瘤確實會完全死亡,同時有細胞凋亡的情形。動物實驗結果顯示,對抗遠端再生成腫瘤,使用預先注射經放射線照射之癌細胞刺激搭配二甲雙胍有較佳之腫瘤抑制效果;此外,在B16F10黑色素瘤上,放射治療的癌症旁觀者效應的確存在,並且搭配預先注射經放射線照射之癌細胞刺激還能有效提升該旁觀者效應。然而,本研究雖有觀察到程度不等的腫瘤抑制效果,但各治療對於小鼠整體存活率之提升皆相當有限。樣本分析上,TUNEL檢定在有預先注射經放射線照射之癌細胞刺激的組別中皆呈現上升的趨勢,然而caspase-3及c-PARP此二細胞凋亡之標記表現在治療組中呈現減少的趨勢,同時Ki67免疫組織化學染色亦顯示本研究之實驗設計無法在腫瘤內部減少此腫瘤增生標誌之表現;免疫螢光染色的部分則可以發現CD3+ T淋巴球於腫瘤區域浸潤之分布和腫瘤生長的抑制情形呈現正相關。 結論:本研究於動物實驗發現放射線引發之旁觀者效應於B16F10黑色素瘤中確實存在,且透過預先注射經放射線照射之癌細胞作為刺激可有效提升此效應;然而,二甲雙胍在協同給予的動物組別中,僅有有限之能力去提升放射線照射之癌細胞刺激對於腫瘤生長之抑制。本研究觀察到巨觀上腫瘤生長抑制之成效,並且在放射線引發之旁觀者效應方面,為未來之前驅研究建立了動物理論基礎。然而,在許多微觀的相關機制分析及驗證上,仍尚待分析及釐清。 | zh_TW |
dc.description.abstract | Background and Purpose: Cancer therapy has become more reliable and efficient in the clinic. However, there is still a need for improving overall survival and dealing with metastasis. Radiotherapy is used to treat approximately half of cancer patients. It kills cancer cells and turns the debris into internal vaccines to patients. Metformin, a commonly used drug in patients with type two diabetes, was reported with anti-cancer and immunomodulation abilities. This study aims to investigate systemic cancer treatment regarding tumor recurrence and radiation-induced bystander effects (RIBE) by using metformin and pre-irradiated cancer cells.
Materials and Methods: B16F10 melanoma was used for both in-vitro and in-vivo study. MTT assay and clonogenic assay were conducted for viability of cells treated with metformin and irradiation, respectively. Transfer medium assay (TMA) was designed to test RIBE in-vitro. Morphology and apoptosis of B16F10 melanoma after 75 Gy irradiation were examined by H&E staining and TUNEL assay. C57BL/6 mice were employed as an tumor model in-vivo. Pre-irradiated (75 Gy) stimulation was utilized to imitate in-situ vaccines formation after radiotherapy, and metformin was given in 200 mg/kg/day. In part A, mice were divided into control (Ctrl), pre-irradiated (pre-IR), metformin (Met) and pre-irradiated combined with metformin (pre-IR + Met) groups. Pre-irradiated cancer cells (3 x 105) were subcutaneously injected on left flanks of mice on Day -14, Day -12 and Day -10. Cells (1 x 105) were subcutaneously injected on right flanks of mice on Day 0. To characterize RIBE, modified setting with pre-irradiated and living B16F10 cancer cells (1:1) were inoculated together on right flank on Day 0 in part B. Four groups included mixed control (Mixed Ctrl), mixed pre-irradiated (Mixed Pre-IR), mixed metformin (Mixed Met) and mixed pre-irradiated combined with metformin (Mixed Pre-IR + Met). Tumor volume and survival fraction were examined for the efficacy study. Mice were sacrificed after cardiac perfusion on Day 16, then tumors were embedded for section staining and lysed for protein quantification. H&E staining, TUNEL assay, Ki67 immunohistochemistry staining and CD3+ immunofluorescent staining were analyzed using tumor sections. Apoptosis related markers were analyzed via Western blot. Results: The toxicity of metformin and irradiation towards B16F10 were examined by MTT assay and clonogenic assay. However, there is no significance between groups treated by TMA in-vitro. Cells were fully destroyed via apoptosis after high-dose irradiation by H&E staining and TUNEL assay. Pre-IR + Met has the best effects on inhibiting B16F10 tumor formation in-vivo in part A, while RIBE is likely to appear on B16F10 melanoma due to the slow tumor formation in part B. Collectively, pre-irradiation could probably enhance RIBE systemically, but with limited effects on overall survival. Moreover, surviving cancer cells could have a higher treatment tolerance owing to remarkable decrease of caspase-3 and c-PARP. Although mouse models showed notable tumor inhibition, data suggested that progressive abilities of tumor could not be reduced by these treatments. Conclusion: Taken together, pre-irradiation in distant sites can effectively enhance RIBE to limit tumor growth. This might be due to the systemic immunomodulation after pre-irradiation inoculation. However, further study is needed to elucidate the mechanisms. This study contributes to the knowledge of RIBE regarding B16F10 melanoma, thus provides novel insights into pre-clinical and clinical radiotherapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T07:21:59Z (GMT). No. of bitstreams: 1 ntu-108-R06548036-1.pdf: 4609729 bytes, checksum: f723c8ad086fecdecb36e94614d6e22e (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii Abstract v 縮寫與翻譯對照表 viii 目錄 x 圖目錄/表目錄 xiii 第一章 緒論 1 1.1 腫瘤 1 1.1.1 癌腫瘤轉移與復發 1 1.2 放射線與放射治療 3 1.2.1 放射線與放射治療引發之免疫反應 3 1.3 二甲雙胍 5 1.3.1 二甲雙胍之抗癌與免疫反應 5 1.3.2 二甲雙胍與放射治療之協同效應 7 1.4 腫瘤細胞株 7 1.5 研究目的 8 第二章 材料與方法 9 2.1 實驗材料 9 2.1.1 癌細胞株 9 2.1.2 實驗動物 9 2.1.3 二甲雙胍 9 2.1.4 銫137放射線照射儀 10 2.2 實驗流程 10 2.3 實驗方法 12 2.3.1 MTT細胞存活率分析 12 2.3.2 培養液置換試驗 13 2.3.3 放射線劑量之克隆檢驗 13 2.3.4 放射線照射之H&E染色觀察 14 2.3.5 放射線照射之TUNEL細胞凋亡檢定 15 2.3.6 動物實驗 16 2.3.7 西方墨點法 18 2.3.8 腫瘤組織切片 19 2.3.9 數值統計與分析 21 第三章 實驗結果 22 3.1 MTT存活率分析 22 3.2 培養液置換試驗 24 3.3 不同劑量照射下B16F10腫瘤細胞之存活情況 26 3.4 放射線照射之B16F10腫瘤細胞H&E染色 27 3.5 B16F10腫瘤細胞受放射線照射之TUNEL細胞凋亡檢定 28 3.6 動物實驗第一部分 29 3.7 動物實驗第二部分 30 3.8 第一部分及第二部分動物實驗之交互比較 32 3.9 小鼠存活率分析 35 3.10 小鼠腫瘤樣本分析 37 第四章 討論 45 4.1 細胞實驗證據 45 4.2 動物實驗 49 4.3 動物實驗腫瘤樣本分析 52 4.4 價值與限制 56 第五章 結論與未來展望 58 第六章 補充圖片 59 第七章 參考文獻 62 | |
dc.language.iso | zh-TW | |
dc.title | 探討預先照射放射線之癌細胞與二甲雙胍對癌腫瘤生長之抑制 | zh_TW |
dc.title | Investigation of Cancer Inhibition Using Pre-irradiated Cancer Cells and Metformin | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 繆希椿(Shi-Chuen Miaw) | |
dc.contributor.oralexamcommittee | 謝銘鈞(Ming-Jium Shieh),張富雄(Fu-Hsiung Chang),郭頌鑫(Sung-Hsin Kuo) | |
dc.subject.keyword | 放射治療,二甲雙胍,放射線引發之旁觀者效應,癌症,黑色素瘤, | zh_TW |
dc.subject.keyword | radiotherapy,metformin,radiation-induced bystander effects,cancer,melanoma, | en |
dc.relation.page | 68 | |
dc.identifier.doi | 10.6342/NTU201901218 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-07-04 | |
dc.contributor.author-college | 工學院 | zh_TW |
dc.contributor.author-dept | 醫學工程學研究所 | zh_TW |
顯示於系所單位: | 醫學工程學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-1.pdf 目前未授權公開取用 | 4.5 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。